Dr Mark Socinski reviews a broad variety of studies, including the evolving role of EGFR inhibitors and immunotherapy in NSCLC, the benefits of immunotherapy plus chemotherapy, and the impact of immune-related adverse events on clinical outcomes in NSCLC.
Medical Oncologist, Thoracic Cancer
Executive Medical Director
AdventHealth Cancer Institute
Orlando, FL
Executive Medical Director
AdventHealth Cancer Institute
Orlando, FL
Related Items
Faculty Perspectives: Comprehensive Biomarker Testing in NSCLC: Opportunities to Advance Precision Medicine published on June 27, 2022
Conference Correspondent published on June 20, 2021 in AACR & ASCO 2021 - Midyear Review